Scinai Immunotherapeutics reported strong revenue growth for the nine months ended September 30, 2026, driven by an acquisition and an expanded CDMO agreement. The significant increase in committed customer orders and revenue suggests positive momentum for the company's CDMO business, despite an operating loss.
Scinai Immunotherapeutics announced a substantial 167% increase in revenue for the nine months ended September 30, 2026, reaching $2.80 million, largely attributed to the integration of operations acquired in February 2026. This growth is further bolstered by an expanded U.S. customer agreement for its CDMO subsidiary, Scinai Biopharma Services Ltd., securing approximately $5.1 million in committed base service fees. The total committed customer orders have surged to $8.32 million, indicating strong future revenue potential. While the company reported an operating loss of $6.56 million and a net loss of $0.39 million, the significant revenue growth and new contracts suggest a positive trajectory for its CDMO business, offering a long-term opportunity for investors despite short-term losses.